Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 First in Human Dose-Escalation Study of ZN-d5 as a Single Agent in Subjects With Non-Hodgkin Lymphoma or Acute Myeloid Leukemia

NCT04500587 is registered in ClinicalTrials.gov with K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04500587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04500587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 First in Human Dose-Escalation Study of ZN-d5 as a Single Agent in Subjects With Non-Hodgkin Lymphoma or Acute Myeloid Leukemia
Lead sponsor
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 13, 2020
Completion date
December 12, 2023
Enrollment
39 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, non hodgkin lymphoma